NCT05892432View on ClinicalTrials.gov

Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 11, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

October 30, 2025

Conditions
Alcohol Use Disorder
Interventions
DRUG

Semaglutide 3 MG [Rybelsus]

Semaglutide 3 mg will be taken for the first 4 weeks of the 8-week trial.

DRUG

Semaglutide 7 MG [Rybelsus]

Semaglutide 7 mg will be taken for the second 4 weeks of the 8-week trial.

DRUG

Placebo

A medically inert placebo medication will be taken for 8 weeks.

Trial Locations (1)

80045

University of Colorado Anschutz Medical Campus, Aurora

All Listed Sponsors
collaborator

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

NIH

lead

University of Colorado, Denver

OTHER

NCT05892432 - Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD) | Biotech Hunter | Biotech Hunter